Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Phase 2

Active, not recruiting

• Conditions: Aggressive Non-Hodgkin Lymphoma
• Interventions: Drug: Pixantrone; Other: Ifosfamide; Other: Etoposide; Other: Rituximab; Procedure: Transplant

• Registration Number: NCT03458260
• Lead Sponsor: The Lymphoma Academic Research Organisation

Brief Summary

This study will evaluate the efficacy of Pixantrone with rituximab, ifosfamide and etoposide as measured by the overall metabolic response rate after 2 cycles of treatment or at permanent treatment discontinuation.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-02-26
• Study First Submitted QC: 2018-03-01
• Study First Posted: 2018-03-08
• Study Start: 2018-03-26
• Primary Completion: 2019-06-15
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-08
• Last Update Posted: 2024-10-09
• Study Completion: 2025-03

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 74

Inclusion Criteria

1. Histologically proven CD20+ aggressive non-Hodgkin lymphoma (diffuse large B-cell lymphoma (DLBCL), de novo or transformed DLBCL from previously untreated low grade non-Hodgkin lymphoma or grade 3b follicular lymphoma) as per the World Health Organization (WHO) 2016 criteria

2. Relapsed or refractory disease, defined as follows:

   1. Patients eligible for ASCT who failed to achieve a Complete Response (CR) after at least one salvage therapy (eg, Rituximab-Etoposide- Methylprednisolone - Cytarabine - Cisplatin (R-ESHAP) or Rituximab- Dexamethasone- High-dose Cytarabine - Cisplatin (R-DHAP), patients who were previously refractory to Rituximab-Ifosfamide-Cytarabine-Etoposide (R-ICE) (stable disease or progressive disease) are not eligible to the study)
   2. Or patients in first relapse after Autologous Stem Cell Transplant (ASCT)
   3. Or patients not eligible for ASCT who failed to achieve a CR after at least one prior treatment (and no more than 4 previous lines) or in relapse after at least one prior treatment (and no more than 4 previous lines).

3. Age > or =18 years

4. Eastern Cooperative Oncology Group (ECOG) performance status < or = 2

5. Subjects must have evaluable disease based on positron emission tomography (PET-CT) scan

6. Minimum life expectancy of 6 months

7. Signed written informed consent

8. Patient covered by any social security system

9. Men must agree to use a barrier method of contraception during the treatment period and until 6 months after the last dose of chemotherapy

10. Women of childbearing potential must agree to use an adequate method of contraception, such as oral contraceptives, intrauterine device, or barrier method of contraception during the treatment period and until 12 months after the last dose of chemotherapy

Exclusion Criteria

1. Any other histological type of lymphoma (Burkitt lymphoma, mantle-cell lymphoma...)

2. Any history of previously treated indolent non-Hodgkin lymphoma

3. Symptomatic central nervous system or meningeal involvement by the lymphoma

4. Contraindication to any drug contained in the Pixantrone with rituximab, ifosfamide and etoposide regimen

5. Treatment with any investigational drug within 28 days before the first study drug administration

6. Any of the following lab abnormalities unless related to the lymphoma or bone marrow infiltration:

   1. Absolute neutrophil count (ANC) < 1.0 G/L
   2. Platelet count < 100 G/L
   3. Creatinine clearance < 40 mL/min for patients < 70 y, or creatinine clearance < 60 mL/min for patients > or = 70 y, by Modification of Diet in Renal Disease (MDRD) method.
   4. Total bilirubin level > 1,5 x Upper Limit of Normal (ULN)
   5. Serum ASpartate Transaminase (AST) or ALanine Transaminase (ALT)> 2,5x ULN

7. Known Human Immunodeficiency Virus (HIV) positive

8. Active hepatitis C virus (HCV) (Positive HCV serology with positive Polymerase Chain Reaction (PCR) for HCV RNA)

9. Active hepatitis B (HB) :

   1. HBsAg positive
   2. HBsAg negative, Ac anti-HBs positive and/or Ac anti-HB core (HBc) positive (Patients who are seropositive due to a history of hepatitis B vaccine are eligible. Patients with Ac anti-HBs positive and/or Ac anti-HBc positive and no history of hepatitis B vaccine are eligible only if PCR for HB virus DNA is negative)

10. Cumulative dose of doxorubicine or equivalent > 450mg/m2

11. Left ventricular ejection fraction (LVEF) < 50% measured by echocardiography or isotopic method

12. Congestive heart failure (any stage from New York Heart Association (NYHA) classification)

13. Uncontrolled arterial hypertension

14. Severe rhythmic heart disease

15. Uncontrolled ischemic heart disease, including patients with stable angina

16. Significant valvular heart disease

17. History of a myocardial infarction within 6 months prior to enrolment

18. Pregnant or lactating females

19. Prior history of malignancies with the exception of non-melanoma skin tumors (basal cell or squamous cell carcinoma) or in situ cervical carcinoma

20. Any serious active disease or co-morbid medical condition according to the investigator's decision

21. Adult person unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness

22. Use of any standard or experimental anti-cancer drug therapy within 28 days before the first study drug administration

23. Use of corticosteroids prior to baseline PET-CT

24. Person deprived of his/her liberty by a judicial or administrative decision

25. Person hospitalized without consent

26. Adult person under legal protection

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Experimental	Transplant	Pixantrone plus rituximab, ifosfamide and etoposide.
Experimental	Ifosfamide	Pixantrone plus rituximab, ifosfamide and etoposide.
Experimental	Etoposide	Pixantrone plus rituximab, ifosfamide and etoposide.
Experimental	Rituximab	Pixantrone plus rituximab, ifosfamide and etoposide.
Experimental	Pixantrone	Pixantrone plus rituximab, ifosfamide and etoposide.

Primary Outcome Measures

Name	Time	Method
Overall Metabolic Response rate (OMR) according to local investigator	After 42 days of treatment (2 cycles) or at permanent treatment discontinuation.	by local investigator according to Lugano classification 2014

Secondary Outcome Measures

Name	Time	Method
Complete Metabolic Response rate (CMR) according to local investigator	After 42 days of treatment (2 cycles of 21 days) or at permanent treatment discontinuation.	according to local investigator
Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)	After 42 or 126 days of treatment (2 or 6 cycles of 21 days) or at permanent treatment discontinuation.
Number of patients for whom Partial Metabolic Response (PMR) is transformed into CMR	After 42 days of treatment (2 cycles of 21 days) or at permanent treatment discontinuation.
Complete Metabolic Response rate (CMR) according to central review	After 42 days of treatment (2 cycles of 21 days) or at permanent treatment discontinuation.	according to local investigator
Overall Metabolic Response rate (OMR) according to central review	After 42 days of treatment (2 cycles of 21 days) or at permanent treatment discontinuation.	according to local investigator
Success of stem cell collection after treatment	After 42 days of treatment (2 cycles of 21 days) or at permanent treatment discontinuation.	Rate of successful stem cell collection
Rate of ASCT	After 42 days of treatment (2 cycles of 21 days) or at permanent treatment discontinuation.	Number of patients who perform an ASCT out of total number of patients

Trial Locations

Locations (22)

Centre Hospitalier de Jolimont; 🇧🇪 Haine-Saint-Paul, Belgium

Clinique Victor Hugo; 🇫🇷 Le Mans, France

AZ Sint Jan; 🇧🇪 Brugge, Belgium

Institut Jules Bordet - Centre des tumeurs de l'ULB; 🇧🇪 Brussels, Belgium

CH d'Avignon; 🇫🇷 Avignon, France

Centre Hospitalier de la Côte Basque; 🇫🇷 Bayonne, France

Centre Hospitalier William Morey; 🇫🇷 Chalon-sur-Saône, France

CHRU de Lille; 🇫🇷 Lille, France

CHU de Poitiers; 🇫🇷 Poitiers, France

Hôpital Robert Debré; 🇫🇷 Reims, France

CHU Jean Minjoz; 🇫🇷 Besançon, France

Hôpital Haut-Lévèque; 🇫🇷 Bordeaux, France

CH de Cornouaille; 🇫🇷 Quimper, France

CHU Lyon Sud; 🇫🇷 Lyon, France

Centre Lacassagne; 🇫🇷 Nice, France

CHU de la Conception; 🇫🇷 Marseille, France

Hopital La Pitié Salpétriere; 🇫🇷 Paris, France

Hôpital St louis; 🇫🇷 Paris, France

Centre Hospitalier Annecy Genevois; 🇫🇷 Pringy, France

CHU de Strasbourg; 🇫🇷 Strasbourg, France

CHU de Rouen; 🇫🇷 Rouen, France

CHU de Tours; 🇫🇷 Tours, France